CENTESSA PHARMACEUTICALS PLC's ticker is CNTA and the CUSIP is 152309100. A total of 41 filers reported holding CENTESSA PHARMACEUTICALS PLC in Q3 2021. The put-call ratio across all filers is - and the average weighting 2.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $205,959 | +32.5% | 31,833 | +26.7% | 0.00% | – |
| Q2 2023 | $155,492 | +78.0% | 25,120 | +10.7% | 0.00% | – |
| Q1 2023 | $87,341 | +212926.8% | 22,686 | +68.9% | 0.00% | – |
| Q4 2022 | $41 | -99.9% | 13,428 | 0.0% | 0.00% | – |
| Q3 2022 | $53,000 | -74.9% | 13,428 | +41.2% | 0.00% | – |
| Q2 2021 | $211,000 | – | 9,513 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Index Venture Life Associates VI Ltd | 9,961,789 | $112,170,000 | 100.00% |
| Medicxi Ventures Management (Jersey) Ltd | 18,123,892 | $204,075,000 | 51.07% |
| Vida Ventures Advisors, LLC | 3,931,818 | $44,272,000 | 16.56% |
| OUP Management Co., LLC | 2,341,891 | $26,370,000 | 11.89% |
| Samsara BioCapital, LLC | 1,459,693 | $16,436,000 | 3.19% |
| VR Adviser, LLC | 1,127,272 | $12,693,000 | 1.74% |
| Affinity Asset Advisors, LLC | 419,144 | $4,720,000 | 1.71% |
| Cormorant Asset Management, LP | 2,489,894 | $28,036,000 | 1.67% |
| Kynam Capital Management, LP | 239,041 | $2,692,000 | 1.44% |
| GENERAL ATLANTIC, L.P. | 9,681,818 | $109,017,000 | 0.84% |